固有免疫分子CD58在人脑胶质瘤中表达及意义的初步研究
作者:
作者单位:

1.湘西土家族苗族自治州人民医院/吉首大学第一附属医院,湖南 吉首 416000;2.吉首大学医学院,湖南 吉首 416000;3.中南大学湘雅医院,湖南 长沙 410008

作者简介:

田志(1981—),男,土家族,神经外科副主任医师,硕士,主要从事脑胶质瘤、脑血管病及颅脑创伤的基础及临床研究。

通信作者:

黄军(1968—),男,神经外科副教授,主任医师,博士,主要从事脑血管病、脑胶质瘤及颅脑脊髓损伤的基础及临床研究。Email:13508488502@163.com。

基金项目:

国家自然科学基金资助项目(编号:81560414);湖南省卫生健康委科研计划项目(编号:20201191)。


A preliminary study on the expression and significance of the innate immune molecular marker CD58 in human gliomas
Author:
Affiliation:

1.Xiangxi Tujia and Miao Autonomous Prefecture People's Hospital/ The First Affiliated Hospital of Jishou University, Jishou, Hunan 416000, China;2.Jishou University School of Medical, Jishou, Hunan 416000, China;3.Xiangya Hospital, Central South University, Changsha, Hunan 410008, China

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 音频文件
  • |
  • 视频文件
    摘要:

    目的 对CD58在胶质瘤中的表达及意义做初步研究。方法 从癌症基因组图谱(TCGA)数据库中获取胶质瘤相关样本的基因测序结果及临床信息,分析胶质母细胞瘤(GBM)组、低级别胶质瘤(LGG)组和非瘤脑组织(Non-tumor)组中CD58的表达差异及生存预后相关性,构建预后模型分析CD58表达与危险度评分关系及CD58高表达组和低表达组的总生存期差异,采用多变量Cox回归分析CD58表达对预后的影响;将40例临床样本分为三组:非瘤脑组织(Non-tumor)组,I、Ⅱ级胶质瘤为低级别胶质瘤(LGG)组,Ⅲ、Ⅳ级胶质瘤为高级别胶质瘤(HGG)组,运用免疫组织化学(免疫组化)检测三组中CD58的表达,并分析各组之间的表达差异。结果 表达差异分析显示,GBM组、LGG组和Non-tumor组的CD58表达依次降低(均P<0.05);危险度评分与CD58表达正相关,表达越高患者生存期越短(P<0.05);多变量Cox回归分析显示CD58表达水平是影响胶质瘤预后的因素,表达水平越高,死亡风险越大;免疫组化结果显示CD58阳性反应物位于细胞胞膜,HGG组阳性细胞数高于LGG组和Non-tumor组(均P<0.05),但三组的阳性例数无差别。结论 CD58在高级别胶质瘤中的表达高于低级别胶质瘤和非瘤脑组织,其表达差异与胶质瘤生存期相关,CD58高表达是胶质瘤预后的危险因素。CD58可以作为判定胶质瘤的恶性程度及预后的一项指标。国际神经病学神经外科学杂志, 2022, 49(3): 1-7.]

    Abstract:

    Objective To investigate the expression and significance of CD58 in gliomas.Methods TCGA database was used to obtain the gene sequencing results and clinical information of glioma-related samples, and the expression of CD58 and its correlation with survival and prognosis were compared between the glioblastoma (GBM) group, low-grade glioma (LGG) group, and non-tumor brain tissue group (non-tumor group). A prognostic model was established to analyze the correlation between CD58 expression and risk score and the difference in overall survival between CD58 high expression group and low expression group. A total of 40 clinical samples were divided into non-tumor brain tissue group (non-tumor group), LGG group (grade I/Ⅱ gliomas), and high-grade gliomas (HGG) group (grade Ⅲ/Ⅳ gliomas), and immunohistochemistry was used to measure the expression of CD58, which was then compared between the three groups.Results The analysis of the difference in CD58 expression showed that the GBM group had the highest CD58 expression, followed by the LGG group and the non-tumor group (P <0.05). Risk score was positively correlated with CD58 expression, and the higher the expression of CD58, the shorter the survival time of patients (P <0.05). The multivariate Cox regression analysis showed that CD58 expression was an influencing factor for the prognosis of glioma, and the higher the expression of CD58, the greater the risk of death. Immunohistochemistry showed that CD58 positive reactants were located in cell membrane, and the HGG group had a significantly higher number of positive cells than the LGG group and the non-tumor group (P <0.05), while there was no significant difference in the number of positive cases between the three groups.Conclusions The expression of CD58 in high-grade gliomas is higher than that in low-grade gliomas and non-tumor brain tissue. The difference in CD58 expression is associated with the survival of gliomas, and the high expression of CD58 is a risk factor for the prognosis of gliomas. Therefore, CD58 can be used as an index to judge the degree of malignancy and the prognosis of glioma. [Journal of International Neurology and Neurosurgery, 2022, 49(3): 1-7.]

    参考文献
    相似文献
    引证文献
引用本文

田志,贾薇,王钊,毛辉,石琼娅,李幸,黄纯海,黄军.固有免疫分子CD58在人脑胶质瘤中表达及意义的初步研究[J].国际神经病学神经外科学杂志,2022,49(3):1-7

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2021-08-16
  • 最后修改日期:2022-06-04
  • 录用日期:
  • 在线发布日期: 2022-07-29
关闭
我刊在喜马拉雅FM开通账号并传播文献

关闭